Studie

A Phase 1/2, multicenter, dose-escalating study to evaluate safety, PK, PD, efficacy of Quizatinibadministered in comb. with re-induction chemotherapy, as single-agent maintenance therapy, in pediatric relapsed, refractory AML with FLT3-ITD inhibition

Erkrankungsgruppe:

Leukämien und MDS

Organsystem:

Blut

Stadium:

Rückfall, Therapierefraktär

Standort:

Essen

EudraCT:

2016-002919-18

Prüfplan-Code:

AC220-A-U202

Phase:

I/II

Prüfsubstanz:

Quizartinib, PIP: EMEA-001821-PIP01-15

Sponsor:

Daiichi Sankyo, Inc., USA